Search

Your search keyword '"Maurel M"' showing total 561 results

Search Constraints

Start Over You searched for: Author "Maurel M" Remove constraint Author: "Maurel M"
561 results on '"Maurel M"'

Search Results

251. La lemmatisation de l'arménien occidental avec NooJ

252. Analyses of volatile organic compounds and refractory organic residues coming from the heating of interstellar ice analogues

253. Identification of monoclonal antibodies from naive antibody phage-display libraries for protein detection in formalin-fixed paraffin-embedded tissues.

254. Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: Results from the VEBIS primary care test-negative design study, September 2023-January 2024.

255. COVID-19 Vaccine Effectiveness in Autumn and Winter 2022 to 2023 Among Older Europeans.

256. Corrigendum to "Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: results from the VEBIS primary care test-negative design study, September 2023-January 2024" [Vaccine 42(19) (2024)].

257. Exploring the effect of clinical case definitions on influenza vaccine effectiveness estimation at primary care level: Results from the end-of-season 2022-23 VEBIS multicentre study in Europe.

258. New insights into the surface Enhanced Raman Scattering (SERS) response of adenine using chemometrics.

259. Insights from structure-activity relationships and the binding mode of peptidic α-ketoamide inhibitors of the malaria drug target subtilisin-like SUB1.

260. COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 BA.1/BA.2 lineages among adults and adolescents in a multicentre primary care study, Europe, December 2021 to June 2022.

261. Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024.

262. Influenza vaccine effectiveness in Europe: Results from the 2022-2023 VEBIS (Vaccine Effectiveness, Burden and Impact Studies) primary care multicentre study.

263. 3D structures of the Plasmodium vivax subtilisin-like drug target SUB1 reveal conformational changes to accommodate a substrate-derived α-ketoamide inhibitor.

264. S -Ethyl-Isothiocitrullin-Based Dipeptides and 1,2,4-Oxadiazole Pseudo-Dipeptides: Solid Phase Synthesis and Evaluation as NO Synthase Inhibitors.

265. Fabrication and characterization of iodine photonic microcells for sub-Doppler spectroscopy applications.

266. Interim 2022/23 influenza vaccine effectiveness: six European studies, October 2022 to January 2023.

267. Dual IRE1 RNase functions dictate glioblastoma development.

268. Influenza vaccine effectiveness against influenza A subtypes in Europe: Results from the 2021-2022 I-MOVE primary care multicentre study.

269. Rapid and Specific Action of Methylene Blue against Plasmodium Transmission Stages.

270. The Phosphodiesterase Inhibitor Tadalafil Promotes Splenic Retention of Plasmodium falciparum Gametocytes in Humanized Mice.

271. High syphilis prevalence and incidence in people living with HIV and Preexposure Prophylaxis users: A retrospective review in the French Dat'AIDS cohort.

272. The effect of social deprivation on the dynamic of SARS-CoV-2 infection in France: a population-based analysis.

273. Stress-induced tyrosine phosphorylation of RtcB modulates IRE1 activity and signaling outputs.

274. Potent Antiplasmodial Derivatives of Dextromethorphan Reveal the Ent -Morphinan Pharmacophore of Tazopsine-Type Alkaloids.

275. Dual IRE1 RNase functions dictate glioblastoma development.

276. A New Thienopyrimidinone Chemotype Shows Multistage Activity against Plasmodium falciparum, Including Artemisinin-Resistant Parasites.

277. Active Targeted Nanoemulsions for Repurposing of Tegaserod in Alzheimer's Disease Treatment.

278. Depressive Symptoms and Cigarette Smoking in Adolescents and Young Adults: Mediating Role of Friends Smoking.

279. The Host Protein Aquaporin-9 is Required for Efficient Plasmodium falciparum Sporozoite Entry into Human Hepatocytes.

280. Contaminant-free end-capped and single-mode acetylene photonic microcell for sub-Doppler spectroscopy.

281. Design of PEGylated Three Ligands Silica Nanoparticles for Multi-Receptor Targeting.

282. Incidence of diabetes in HIV-infected patients treated with first-line integrase strand transfer inhibitors: a French multicentre retrospective study.

283. Patterning of educational attainment across inflammatory markers: Findings from a multi-cohort study.

284. Skin diseases affecting a population occupationally exposed to terrestrial fauna and flora in Brittany over a 15-year period.

285. The presence of PEG on nanoparticles presenting the c[RGDfK]- and/or ATWLPPR peptides deeply affects the RTKs-AKT-GSK3β-eNOS signaling pathway and endothelial cells survival.

286. Control of anterior GRadient 2 (AGR2) dimerization links endoplasmic reticulum proteostasis to inflammation.

287. Tailoring modal properties of inhibited-coupling guiding fibers by cladding modification.

288. A cost-effectiveness analysis comparing the originator follitropin alfa to its biosimilars in patients undergoing a medically assisted reproduction program from a French perspective.

289. Differential activity of methylene blue against erythrocytic and hepatic stages of Plasmodium.

290. Optimized inhibited-coupling Kagome fibers at Yb-Nd:Yag (8.5  dB/km) and Ti:Sa (30 dB/km) ranges.

291. Dual IRE1 RNase functions dictate glioblastoma development.

292. [How to evaluate side effects in a clinical trial?]

293. Better understanding of water quality evolution in water distribution networks using data clustering.

294. [Negative symptoms: which antipsychotics?].

295. Controlling the unfolded protein response-mediated life and death decisions in cancer.

296. Plasmodium falciparum full life cycle and Plasmodium ovale liver stages in humanized mice.

297. Critical role of IL-33 receptor ST2 in experimental cerebral malaria development.

298. [Affective disorders and personality disorders].

299. Endoplasmic reticulum stress: at the crossroads of inflammation and metabolism in hepatocellular carcinoma development.

300. Getting RIDD of RNA: IRE1 in cell fate regulation.

Catalog

Books, media, physical & digital resources